What do systematic reviews say?

Fluoxetine vs moclobemide

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with moclobemide (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.7 [0.32, 1.56]
  6 studies · 679 participants
  Moderate

Fluoxetine vs moclobemide

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with moclobemide (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.07 [0.64, 1.8]
  7 studies · 721 participants
  Moderate

Fluoxetine vs nefazodone

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs nefazodone

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 271 participants
  Moderate

Fluoxetine vs nefazodone

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with nefazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.54 [0.22, 1.31]
  3 studies · 161 participants
  Moderate

Fluoxetine vs nefazodone

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with nefazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.71 [0.05, 10.71]
  3 studies · 161 participants
  Moderate

Fluoxetine vs ABT‐200

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with ABT‐200 (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.24 [0.03, 2.2]
  1 study · 144 participants
  Low

Fluoxetine vs nefazodone

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with nefazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.76 [0.32, 1.81]
  4 studies · 286 participants
  Moderate

Fluoxetine vs paroxetine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with paroxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.23 [0.93, 1.65]
  9 studies · 1574 participants
  Moderate

Fluoxetine vs paroxetine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 2061 participants
  Moderate

Fluoxetine vs paroxetine

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with paroxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.98 [0.81, 1.2]
  10 studies · 1848 participants
  Moderate

Fluoxetine vs paroxetine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with paroxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.75 [0.41, 1.39]
  4 studies · 1005 participants
  Moderate

Fluoxetine vs paroxetine

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with paroxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.85 [0.62, 1.16]
  9 studies · 1509 participants
  Moderate

Fluoxetine vs phenelzine

It is very uncertain whether fluoxetine changes failure to respond (reduction ≥ 50% on HDRS) compared with phenelzine (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.42 [0.27, 7.34]
  1 study · 40 participants
  Very low

Fluoxetine vs phenelzine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low

Fluoxetine vs phenelzine

It is very uncertain whether fluoxetine changes failure to complete ‐ total ‐ compared with phenelzine (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.18 [0.01, 4.01]
  1 study · 40 participants
  Very low

Fluoxetine vs phenelzine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Exercise vs pharmacological treatments

• Exercise for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 278 participants
  Moderate

Exercise vs pharmacological treatments

• Exercise for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 1 participants
  Moderate

Exercise vs pharmacological treatments

• Exercise for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 3 participants
  Moderate